leisure time -WSS

leisure time

author：leisure time 2025-10-01 16:40:43 - browse：55

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year.

ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.

ReNAgade was able to capitalize on that excitement when it raised a $300 million Series A round led by MPM Capital’s BioImpact Capital and F2 Ventures. But in recent days, the company decided to lay off around 10% of its 100-person team, according to a company statement and former employees’ posts on social media.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Living with Hashimoto's and celiac disease, and med school, too

WSS

Medical device lobby: We're tired of waiting on Medicare coverage

Cancer drug shortages' outsize impact on ovarian cancer patients

Medical device lobby: We're tired of waiting on Medicare coverage

Obesity now affects over 1 billion people worldwide, study finds

An interview with Robert F. Kennedy Jr. on vaccines

Clinical trials must include more disabled people

focus

leisure time

Wikipedia

Heart attack and stroke risk calculators need revising

Flu vaccine offering decent levels of protection this winter, new data show

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Congress gives doctors Medicare pay bump

State Dept. review finds Biden bears some blame for Afghanistan failures

ALS groups 'won't be played again' by the FDA, drug sponsors

Medicare proposal to cover medical devices draws a mixed reaction

Congress must give Medicare recipients genetic counseling access

BioMarin wins approval for gene therapy to treat hemophilia A

Clinical trials giant ICON acquires HumanFirst

focus

Listen: Racing for gene therapy & a pioneering approval

An interview with Robert F. Kennedy Jr. on vaccines

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Flu vaccine offering decent levels of protection this winter, new data show

In search for therapies for solid tumors, companies turn to claudin

hotspot

Wikipedia

entertainment

focus